Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors.
OBJECTIVE
To evaluate retinoblastoma regression patterns following chemoreduction and adjuvant therapy.


METHODS
A total of 557 retinoblastomas.


METHODS
A retrospective medical record review following 6 cycles of chemoreduction and tumor consolidation (thermotherapy or cryotherapy). Regression patterns included type 0 (no remnant), type 1 (calcified remnant), type 2 (noncalcified remnant), type 3 (partially calcified remnant), and type 4 (flat scar).


METHODS
Regression pattern.


RESULTS
Retinoblastoma regressions were type 0 (n = 10), type 1 (n = 75), type 2 (n = 28), type 3 (n = 127), and type 4 (n = 317). Tumors with an initial thickness of 3 mm or less regressed most often to type 4 (92%), those 3 to 8 mm regressed to type 3 (34%) or type 4 (40%), and those thicker than 8 mm regressed to type 1 (40%) or type 3 (49%). Factors predictive of type 1 regression included larger tumor base and closer foveolar proximity. Factors predictive of type 3 included older age, larger tumor base, macular location, closer foveolar proximity, and lack of consolidation. Factors predictive of type 4 included familial hereditary pattern, smaller tumor base, greater foveolar distance, and tumor consolidation.


CONCLUSIONS
Following chemoreduction, most small retinoblastomas result in a flat scar, intermediate tumors in a flat or partially calcified remnant, and large tumors in a more completely calcified remnant.
Shields
Carol L
CL
The Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, 840 Walnut St, Ste 1440, Philadelphia, Pennsylvania 19107, USA. carol.shields@shieldsoncology.com
Palamar
Melis
M
Sharma
Pooja
P
Ramasubramanian
Aparna
A
Leahey
Ann
A
Meadows
Anna T
AT
Shields
Jerry A
JA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002114:Calcinosis / Q000473:pathology; D016190:Carboplatin / Q000627:therapeutic use; D002675:Child, Preschool; D017679:Cryotherapy; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007223:Infant; D008297:Male; D019572:Retinal Neoplasms / Q000145:classification / Q000473:pathology* / Q000628:therapy; D012175:Retinoblastoma / Q000145:classification / Q000473:pathology* / Q000628:therapy; D012189:Retrospective Studies; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D005047:Etoposide; D016190:Carboplatin